Cannabis Science Inc (OTCMKTS:CBIS) Can Now Bid For Government Contracts

Cannabis Science Inc (OTCMKTS:CBIS)

Cannabis Science Inc (OTCMKTS:CBIS)

Cannabis Science Inc (OTCMKTS:CBIS) can now bid for government contracts having received a Commercial and Government Entity Code from the Department of Defense. The company is now listed with all US companies eligible for Federal Government Contracts, having completed registration in the U.S Government System for Award Management (SAM).

Government Contracts Opportunity

The SAM database listing for Cannabis Science Inc (OTCMKTS:CBIS) means the U.S government can award the company with contract initiatives and research and development projects. The clearance marks yet another milestone achievement for the company given that the Federal government issues over $190 billion contracts a year as well as over $450 billion in grants.

“Achieving eligibility to access contracting opportunities with the U.S. Federal Government is a significant step for Cannabis Science. I believe we can leverage the unique experience and expertise of our company to win new business and grow Cannabis Science’s revenue base. We also plan to work closely with our strategic partners and collaborators to access Federal contracting and grant opportunities,” said CEO and Co-Founder Raymond C. Dabney.

Cannabis Science Inc (OTCMKTS:CBIS) now plans to pursue funding opportunities with a number of collaborators, as it seeks to remain compliant for government contracts.

Suppository Milestone

Separately, Cannabis Science Inc (OTCMKTS:CBIS) has released the first batch of its cannabinoid suppositories for male and female patients. Designed to aid in symptoms related to cancer, anxiety, and severe pain, the unisex suppository further expands the Cannabis Science portfolio of self-medicating products. These types of medications are designed as an alternative for individuals who find it hard to take medication orally – additionally, suppositories are 50-70% more efficient than ingested cannabis. These types of drugs have also proved to be effective in treating pelvic and lower gastrointestinal conditions.

“This is another ground-breaking product release. We expect our suppository regimens to help address a significant demand for cannabinoid-based medicines targeting several patient-specific indications. Through this limited release of unisex regimens to self-medicating patients, we expect to track the use of these products through the dispensary, and observe the effectiveness of this particular formulation and delivery system,” said Dr. Allen Herman, Cannabis Science Chief medical officer

Cannabis Science Inc (OTCMKTS:CBIS) stock was up by 0.51% in Wednesday’s trading session, ending the day at $0.0597 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CBIS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.

Previous ArticleNext Article
Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Leave a Reply

Your email address will not be published. Required fields are marked *